Diligent Announces Diligent AI to Empower Governance, Risk and Compliance Professionals to Better Manage and Respond to Risk
11.6.2024 15:00:00 EEST | Business Wire | Press release
Diligent, a leading GRC SaaS company, today announced Diligent AI, a powerful set of artificial intelligence capabilities within the Diligent One Platform that enhance how organizations understand, anticipate and mitigate risks. Diligent AI will enable users to identify risks, safeguard data and democratize the decision-making processes, driving resilience and empowering organizations with certainty and clarity like never before.
"Company leaders face a dynamic and evolving risk environment. It’s imperative to turn data into strategic intelligence to anticipate and prevent risks, rather than just respond to them,” said Brian Stafford, President and CEO of Diligent. “Diligent’s AI-enhanced platform is uniquely positioned to connect all aspects of governance, risk and compliance, delivering customized insights to elevate governance and clarify risk.”
Diligent AI helps leaders amplify critical insights while working together across the organization, using risk as a shared language. Leaders can expand resources and achieve greater results through integrated automation, enhance stakeholder communication by tailoring information to board members, chief financial officers, chief risk officers and other executives, and enhance decision making by breaking down information silos across governance, risk and compliance (GRC) functions.
Register for the first session in Diligent’s AI webinar series starting on June 13, where Diligent leaders and experts will discuss Diligent AI capabilities and how they:
Elevate Governance for Boards and Leaders:
- Creating efficient, context-aware summaries of board materials to help directors easily digest information and glean insights.
- Providing AI-powered insights into a company’s ESG focus and self-disclosed risk factors, enabling peer comparison and helping to identify industry trends.
- Quickly assisting with boards-related questions through a 24/7 AI-powered virtual assistant.
Clarify Risk for Audit, Risk and Compliance Teams:
- Simplifying the tedious process of mapping internal controls to regulatory requirements, enabling GRC professionals to efficiently demonstrate compliance.
- Identifying changes between two versions of the same regulation, categorizing them as significant, moderate or minor, enabling users to efficiently update related policies, risks and controls.
- Empowering users to create, edit and troubleshoot data integrations and data analytics scripts using plain language. This brings Diligent's powerful robotics capabilities (also known as ACL Analytics) to a broader audience.
Additional capabilities will be added to Diligent AI over the coming months that empower GRC professionals to better mitigate risks and stay on top of changing regulatory requirements, and help corporate directors govern more effectively amidst escalating risks and information overload.
“Diligent AI adds to the breadth of the Diligent One Platform by enabling leaders to more quickly and effectively respond to risk in a competitive environment,” said Phil Lim, Global AI Champion at Diligent. “Our thoughtful and ethical approach to AI use, guided by industry-leading principles, means customers can feel secure in knowing that AI interacts with their data safely and securely, and only with their prior consent.”
The use of Generative AI in GRC must uphold the highest standards of safety and security, and Diligent has committed to the safe, secure and ethical use of AI through its guiding principles. This ensures users’ data stays their own, generated content is clearly labelled and users must always opt-in before using AI with their data. Learn more about Diligent’s AI Principles here.
About Diligent
Diligent is the leading GRC SaaS company, empowering more than 1 million users and 700,000 board members and leaders to make better decisions, faster. The Diligent One Platform helps organizations connect their entire GRC practice — including governance, risk, compliance, audit and ESG — to bring clarity to complex risk, stay ahead of regulatory changes and deliver impactful insights, in one consolidated view. Learn more at diligent.com.
Follow Diligent on LinkedIn, X (Twitter) and Facebook.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240611912292/en/
Contacts
Media
Julia Stoyanov
Communications Director, Diligent
+1 (604) 669-4225
Jhanbury@diligent.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Smartsheet Unveils vsActual: The AI-Native Platform that Connects Strategy to Execution at ENGAGE 20264.11.2026 19:00:00 EET | Press release
Smartsheet, the AI-powered enterprise work management platform, today unveiled a new AI-native strategic planning and execution product at ENGAGE 2026, its annual customer conference. vsActual is designed to solve the two biggest obstacles to enterprise execution: siloed work scattered across disconnected systems and teams, and the manual tracking and reporting that keeps individuals and executives from seeing problems until it’s too late. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104989965/en/ Today, Smartsheet unveiled a new AI-native strategic planning and execution product, vsActual. AI is helping individuals move faster than ever, but it's also making it harder to keep everyone moving in the same direction. In fact, a PMI research report found that leaders cited the disconnect between planning and execution as the biggest barrier to reinventing their businesses, and VentureBeat Intelligence found that 64% of res
SES Achieves Optical Communications Milestone for Future meoSphere Network4.11.2026 19:00:00 EET | Press release
SES, in collaboration with leading space technology partners, has successfully demonstrated a bi-directional optical communications link between ground and space through its meoSphere Pathfinder 1 mission, marking an important milestone in the development of the company's next-generation meoSphere network. The achievement validates a critical technology that will support future high-capacity, secure and flexible connectivity services. During the demonstration, SES successfully transmitted video messages from CEO Adel Al-Saleh over a bidirectional optical communications link between Cailabs' optical ground station in Rennes, France, and an SES payload flying on K2’s GRAVITAS mission on their Mega-class satellite platform. The mission utilized a Mynaric CONDOR optical terminal onboard. SES designed, developed, and operated the optical mission and developed automation software that enabled the demonstration. Thales Alenia Space supported system assembly, integration, testing and operation
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 17:44:00 EET | Press release
Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the production line. In-Factory Profile Provisioning (IFPP) addresses this challenge by enabling conne
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom